AstraZeneca to retire MedImmune brand amid restructuring

pharmafile | February 15, 2019 | News story | Medical Communications AstraZeneca, Business, MedImmune, R&D, biologics, restructuring 

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D units.

The announcement comes just a month after AstraZeneca announced organisational changes which will see the creation of therapy area specific R&D units.

AstraZeneca acquired MedImmune in 2007, running the firm as a separate biologics unit. However the restructuring will see the company integrated into AstraZeneca’s new R&D units.

The changes will not affect MedImmune’s ongoing partnerships and collaborations. AstraZeneca did not offer insight as to whether the restructuring would result in changes to management; however a spokesperson suggested that no layoffs are expected.

 The news comes after a number of high profile resignations. Nevertheless recent figures show that  AstraZeneca’s fourth quarter revenue jumped 11% year on year, reaching $6.4 billion

“As we recently entered a new phase in our strategic development, we have refined our organisation to position ourselves for the next phase of our journey,” CEO Pascal Soriot said.

Louis Goss

Related Content

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …

FDA approves AstraZeneca’s Ultomiris for NMOSD treatment

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …

Latest content